

20 November 2025

To

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051

NSE Scrip Symbol: SaiLife

To

BSE Limited

Phiroze Jeejeebhoy Towers, Dalal Street

Mumbai - 400001

BSE Scrip Code: 544306

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with SEBI Circular on the Industry Standards Note on Regulation 30 dated 25 February 2025, this is to inform you that an Order dated 19th November, 2025 was passed by the Joint Commissioner of Commercial Taxes (Appeals), Kalaburagi u/s 107 (11) of the Karnataka Goods and Services Tax Act, 2017 and the Central Goods and Services Tax Act, 2017.

The details as required in terms of Regulation 30 read with sub-para 20 of Para A of Part A of Schedule III of the Listing Regulations is enclosed herewith as **Annexure - I**.

This is for your information and records.

Thank you.

For Sai Life Sciences Limited

Runa Karan Company Secretary & Compliance Officer Membership No.: A13721

Encl: As above

Sai Life Sciences Limited (CIN: L24110TG1999PLC030970)

Telangana, India.

Registered office



Annexure-I

Disclosures with respect to sub para 20 of Para A of Part A of Schedule III of Listing Regulations read with SEBI Master Circular dated 11 November 2024:

Sr. No.	Particulars	Details
1.	Name of the authority	Joint Commissioner of Commercial Taxes (Appeals), Kalaburagi
2.	Nature and details of the action taken, initiated or order passed	Orders passed under Section 107 (11) of the Goods and Services Tax Act, 2017, with demand of IGST amounting to INR 20,84,77,738, Interest amounting to INR 13,75,10,920, Penalty amounting to INR 2,08,47,774.
3.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	19 November 2025 at 04:10 PM
4.	Details of the violation/ contravention committed or alleged to be committed	The demand is raised in respect of taxability of intermediary services received from the subsidiary M/s. Sai Life Sciences Inc., USA under the reverse charge mechanism for the period July 2017 to March 2022.
5.	Impact on financial, operation, or other activities of the listed entity, quantifiable in monetary terms to the extent possible	Based on the Company assessment, an appeal will be filed, and the Company is hopeful of favourable outcome at the Tribunal level and does not reasonably expect the said Order to have any material financial impact on the Company.

Contact us